PL238121B1 - Cis-(4S,5S,6R)-5-(1-bromethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one and method for obtaining it - Google Patents
Cis-(4S,5S,6R)-5-(1-bromethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one and method for obtaining it Download PDFInfo
- Publication number
- PL238121B1 PL238121B1 PL425548(22)20180515A PL42554818A PL238121B1 PL 238121 B1 PL238121 B1 PL 238121B1 PL 42554818 A PL42554818 A PL 42554818A PL 238121 B1 PL238121 B1 PL 238121B1
- Authority
- PL
- Poland
- Prior art keywords
- dimethylphenyl
- dihydrofuran
- cis
- bromoethyl
- hex
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 11
- AVSAPYYIFVSGNF-ITKZLYELSA-N (E,3R)-3-(2,5-dimethylphenyl)hex-4-enoic acid Chemical compound CC1=C(C=C(C=C1)C)[C@H](CC(=O)O)\C=C\C AVSAPYYIFVSGNF-ITKZLYELSA-N 0.000 claims abstract description 8
- 238000010722 bromolactonization reaction Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 238000004440 column chromatography Methods 0.000 claims abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 125000006083 1-bromoethyl group Chemical group 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- RSMFTPWQSUSOGH-VUDGCMKMSA-N CC1=C(C=C(C=C1)C)[C@H](CC)\C=C\C Chemical compound CC1=C(C=C(C=C1)C)[C@H](CC)\C=C\C RSMFTPWQSUSOGH-VUDGCMKMSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 241000282465 Canis Species 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- -1 2,5-dimethylphenyl ring Chemical group 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- SMUVABOERCFKRW-UHFFFAOYSA-N 2,5-Dimethylbenzaldehyde Chemical compound CC1=CC=C(C)C(C=O)=C1 SMUVABOERCFKRW-UHFFFAOYSA-N 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940081310 piperonal Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Landscapes
- Furan Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Zgłoszenie dotyczy optycznie czynnego cis-(4S,5S,6R)-5-(1-bromoetylo)-4-(2',5'-dimetylofenylo)-dihydrofuran-2-onu o wzorze 1, oraz sposobu jego otrzymywania. Sposób ten polega na tym, że kwas (R,E)-3-(2',5'-dimetylofenylo)-heks-4-enowy poddaje się reakcji bromolaktonizacji otrzymując mieszaninę produktów, z której następnie metodą chromatografii kolumnowej wydziela się w postaci czystej cis-(4S,5S,6R)-5-(1-bromoetylo)-4-(2',5'-dimetylofenylo)-dihydrofuran-2-on.The application relates to optically active cis-(4S,5S,6R)-5-(1-bromoethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one of formula 1, and a method for its preparation. This method consists in subjecting (R,E)-3-(2',5'-dimethylphenyl)-hex-4-enoic acid to a bromolactonization reaction to obtain a mixture of products, from which cis-(4S,5S,6R)-5-(1-bromoethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one is then isolated in pure form by column chromatography.
Description
Przedmiotem wynalazku jest optycznie czynny c/s-(4S,5S,6R)-5-(1-bromoetylo)-4-(2’,5’-dimetylofenylo)-dihydrofuran-2-on o wzorze 1 przedstawionym na rysunku.The present invention relates to the optically active c / s- (4S, 5S, 6R) -5- (1-bromoethyl) -4- (2 ', 5'-dimethylphenyl) -dihydrofuran-2-one of the formula 1 shown in the drawing.
Przedmiotem wynalazku jest również sposób otrzymywania bromolaktonu o wzorze 1 z kwasu (R,E)-3-(2',5'-dimetylofenylo)-heks-4-enowegoThe subject of the invention is also a method of obtaining bromolactone of formula 1 from (R, E) -3- (2 ', 5'-dimethylphenyl) -hex-4-enoic acid.
Optycznie czynny 3-fenylo-5-bromo-y-lakton o wzorze 1 może znaleźć zastosowanie w przemyśle farmaceutycznym jako związek o działaniu antynowotworowym.The optically active 3-phenyl-5-bromo-γ-lactone of the formula I can find application in the pharmaceutical industry as a compound with anti-tumor activity.
ó-Bromo-y-lakton z pierścieniem 2,5-dimetylofenylowym o wzorze 1 wykazuje aktywność antyproliferacyjną in vitro wobec psich nowotworowych linii komórkowych: chłoniaka B-komórkowego (CLBL-1) oraz przewlekłej białaczki B-komórkowej (CLB70), Związek ten może znaleźć zastosowanie w farmacji jako składnik leków antynowotworowych.β-Bromo-γ-lactone with a 2,5-dimethylphenyl ring of formula 1 shows antiproliferative activity in vitro against canine tumor cell lines: B-cell lymphoma (CLBL-1) and chronic B-cell leukemia (CLB70). find application in pharmacy as a component of anti-cancer drugs.
Dotychczas znane były optycznie czynne jodolaktony z pierścieniem 2,5-dimetylofenylowym wykazujące aktywność antyproliferacyjną in vitro wobec linii komórkowych: białaczki ludzkiej (Jurkat), psiej białaczki B-komórkowej (GL-1), psiej osteosarkomy (D17) oraz psiego chłoniaka B-komórkowego (CLBL-1) (Gładkowski W., Skrobiszewski A., Mazur M., Gliszczyńska A., Czarnecka M., Pawlak A., Obmińska-Mrukowicz B., Maciejewska G., Białońska A. Chiral 5-iodo-y-lactones derived from cuminaldhyde, 2,5-dimethylbenzaldehyde and piperonal: chemoenzymaticsynthesis and antiproliferative activity. Tetrahedron: Asymmetry, 2016, 27, 227-237; opis wynalazku P.415782 oraz P.415783).So far, optically active iodolactones with a 2,5-dimethylphenyl ring have been known, showing antiproliferative activity in vitro against the following cell lines: human leukemia (Jurkat), canine B-cell leukemia (GL-1), canine osteosarcoma (D17) and canine B-cell lymphoma (CLBL-1) (Gładkowski W., Skrobiszewski A., Mazur M., Gliszczyńska A., Czarnecka M., Pawlak A., Obmińska-Mrukowicz B., Maciejewska G., Białońska A. Chiral 5-iodo-y- lactones derived from cuminaldhyde, 2,5-dimethylbenzaldehyde and piperonal: chemoenzymaticsynthesis and antiproliferative activity. Tetrahedron: Asymmetry, 2016, 27, 227-237; invention description P.415782 and P.415783).
Wynalazek, dotyczy sposobu wytwarzania na drodze syntezy chemicznej optycznie czynnego c/s-(4S,5S,6R)-5-(1-bromoetylo)-4-(2’,5’-dimetylofenylo)-heks-4-enowego.The invention relates to a chemical synthesis of optically active c / s- (4S, 5S, 6R) -5- (1-bromoethyl) -4- (2 ', 5'-dimethylphenyl) -hex-4-ene.
Istota wynalazku polega na tym, że kwas (R,E)-3-(2’,5’-dimetylofenylo)-heks-4-enowy poddaje się reakcji z N-bromoimidem kwasu bursztynowego a z otrzymanej mieszaniny bromolaktonów wydziela się metodą chromatografii kolumnowej czysty c/s-(4S,5S,6R)-5-(1-brometylo)-4-(2',5-dimetylofenylo)dihydrofuran-2-on.The essence of the invention is that (R, E) -3- (2 ', 5'-dimethylphenyl) -hex-4-enoic acid is reacted with N-bromosuccinimide and the resulting mixture of bromolactones is separated by column chromatography. c / s- (4S, 5S, 6R) -5- (1-bromethyl) -4- (2 ', 5-dimethylphenyl) dihydrofuran-2-one.
Korzystnie jest, gdy reakcję bromolaktonizacji kwasu (R,E)-3-(2’,5’-dimetylofenylo)-heks-4-enowego prowadzi się w tetrahydrofuranie.Preferably, the bromolactonization reaction of (R, E) -3- (2 ', 5'-dimethylphenyl) -hex-4-enoic acid is carried out in tetrahydrofuran.
Korzystnie jest także, gdy reakcję, bromolaktonizacji kwasu (R,E)-3-(2’,5’-dimetylofenylo)-heks-4-enowego prowadzi się w obecności katalitycznych ilości kwasu octowego.It is also preferred that the bromolactonization reaction of (R, E) -3- (2 ', 5'-dimethylphenyl) -hex-4-enoic acid is carried out in the presence of catalytic amounts of acetic acid.
Zasadniczą zaletą wynalazku jest otrzymanie cis-(4S,5S,6R)-5-(1-bromoetylo)-4-(2',5'-dimetylofenylo)-dihydrofuran-2-onu o wzorze 1 wykazującego aktywność antyproliferacyjną in vitro z bardzo wysokim nadmiarem enancjomerycznym (ee = 96%).The main advantage of the invention is the preparation of cis- (4S, 5S, 6R) -5- (1-bromoethyl) -4- (2 ', 5'-dimethylphenyl) -dihydrofuran-2-one of the formula 1 showing antiproliferative activity in vitro with a very high high enantiomeric excess (ee = 96%).
Tabela 1 przedstawia wyniki testów biologicznych in vitro otrzymanego laktonu w stosunku do wybranych linii komórek nowotworowych. Testy przeprowadzono według metody opisanej w literaturze(Ferrari M., Fornasiero M.C., Isetta A.M. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro Journal. Journal of Immunological Methods 1990 131, 165-172).Table 1 shows the results of in vitro biological tests of the obtained lactone against selected tumor cell lines. The tests were performed according to the method described in the literature (Ferrari M., Fornasiero M.C., Isetta A.M. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro Journal. Journal of Immunological Methods 1990 131, 165-172).
Tabela 1Table 1
ICM - stężenie związku, przy którym żywotność komórek wynosi 50%IC M - concentration of the compound at which cell viability is 50%
SEM - błąd standardowy średniejSEM - standard error of the mean
Wynalazek jest bliżej objaśniony w przykładzie wykonaniaThe invention is explained in more detail in an exemplary embodiment
Przykład. W kolbie okrągłodennej umieszcza się 1,24 g kwasu (R,E)-3-(2’,5’-dimetylofenylo)heks-4-enowego, 2,5 g N-bromoimidu kwasu bursztynowego (NBS), 50 cm3 THF i kroplę kwasu octowego. Całość miesza się na mieszadle magnetycznym w temperaturze pokojowej kontrolując przebieg reakcji za pomocą chromatografii cieńkowarstwowej heksan : aceton w stosunku objętościowym 7:1. Po całkowitym przereagowaniu substratu całość przenosi się do rozdzielacza, rozcieńcza 30 cm3 eteru dietylowego i przemywa nasyconym roztworem NaHCOs (trzykrotnie po 20 cm3). Warstwę organiczną zobojętnia się solanką wobec papierka wskaźnikowego i osusza bezwodnym siarczanem magnezu. Po odsączeniu suszącego odparowuje się rozpuszczalnik. Otrzymuje się mieszaninę bromolaktonów,Example. Place 1.24 g of (R, E) -3- (2 ', 5'-dimethylphenyl) hex-4-enoic acid, 2.5 g of N-bromosuccinimide (NBS), 50 cm 3 THF in a round bottom flask. and a drop of acetic acid. The whole is stirred on a magnetic stirrer at room temperature, while the course of the reaction is controlled by means of thin-layer chromatography hexane: acetone in the volume ratio of 7: 1. When the substrate is completely consumed, it is transferred to a separating funnel, diluted with 30 cm 3 of diethyl ether and washed with saturated NaHCO 3 solution (3 times 20 cm 3 ). The organic layer is neutralized with brine against a indicator paper and dried with anhydrous magnesium sulfate. After the drying agent was filtered off, the solvent was evaporated. A mixture of bromolactones is obtained,
PL 238 121 B1 z której metodą chromatografii kolumnowej żelu krzemionkowym przy zastosowaniu jako eluentu mieszaniny heksan : aceton w stosunku objętościowym 20:1 wydziela się jako jeden produktów cis -(4 S ,5 S ,6 R)-5-(1-bromoetylo)-4-(2’,5’-dimetylo)-hydrofuran-2-on w ilości 0,2 g (12% wydajności teoretycznej).From which by silica gel column chromatography using a hexane: acetone mixture in a 20: 1 volume ratio as eluent, cis - (4S, 5S, 6R) -5- (1-bromoethyl) products are separated -4- (2 ', 5'-dimethyl) -hydrofuran-2-one in the amount of 0.2 g (12% of theory).
Dane fizyczne i spektroskopowe otrzymanego cis-(4S,5S,6R)-5-(1-bromoetylo)-4-dimetylofenylo)-dihydrofuran-2-onu są następujące: bezbarwne kryształy, temperatura topnienia 113-119°C.The physical and spectroscopic data of the obtained cis- (4S, 5S, 6R) -5- (1-bromoethyl) -4-dimethylphenyl) -dihydrofuran-2-one are as follows: colorless crystals, m.p. 113-119 ° C.
Rf = 0 47 heksan/aceton, 3:1 ), [a]20 = + 66,6 (c 0,95; CH2CI2, ee = 96%)Rf = 0.47 hexane / acetone, 3: 1), [a] 20 = + 66.6 (c 0.95; CH2Cl2, ee = 96%)
1H NMR, δ 1,80 (d, J = 6,6 Hz, 3H, CH3-7), 2,29 (s, 3H, CH3-5'), 2,37 (s, 3H, CH3-2'), 2,61 (dd, J = 18,0, 1,8 Hz, 1H, jeden z CH2-3), 3,09 (dd, J = 18,0, 9,0 Hz, 1H, jeden z CH2-3), 3,80 (dublet kwartetów, J = 9,6, 6,6 Hz, 1H, H-6 ddd, J = 9,0, 6,0, 1,8 Hz, 1H, H-4), 4,75 (dd, J = 9,6, 6,0 Hz, 1H, H-5), 6,86 (s, 1H, H-6'), 7,00 (m, 1H, H-4'), 7,06 (d, J = 7,8 Hz, 1H, H-3');1H NMR, δ 1.80 (d, J = 6.6Hz, 3H, CH3-7), 2.29 (s, 3H, CH3-5 '), 2.37 (s, 3H, CH3-2' ), 2.61 (dd, J = 18.0, 1.8 Hz, 1H, one of CH2-3), 3.09 (dd, J = 18.0, 9.0 Hz, 1H, one of CH2 -3), 3.80 (quartet doublet, J = 9.6, 6.6 Hz, 1H, H-6 ddd, J = 9.0, 6.0, 1.8 Hz, 1H, H-4) , 4.75 (dd, J = 9.6, 6.0 Hz, 1H, H-5), 6.86 (s, 1H, H-6 '), 7.00 (m, 1H, H-4 '), 7.06 (d, J = 7.8Hz, 1H, H-3');
13C NMR, δ 19,87 (CH3-2'), 21,18 (CH3-5'), 23,37 (C-7), 38,41 (C-3), 38,53 (C-4), 45,29 (C-S), 86,76 (C-5), 126,45 (C-6'), 128,47 (C-4'), 130,91 (C-31), 133,29 (C-2'), 136,11 (C-5'), 136,42 (C-1'), 176,41 (C-2); 13 C NMR, δ 19.87 (CH3-2 '), 21.18 (CH3-5'), 23.37 (C-7), 38.41 (C-3), 38.53 (C-4 ), 45.29 (CS), 86.76 (C-5), 126.45 (C-6 '), 128.47 (C-4'), 130.91 (C-31), 133.29 (C-2 '), 136.11 (C-5'), 136.42 (C-1 '), 176.41 (C-2);
IR (cm-1): 1774 (s) 1506 (w) 1185 (s), 1147 (s), (989) (m), 823 (m), 629 (m).IR (cm -1 ): 1774 (s) 1506 (w) 1185 (s), 1147 (s), (989) (m), 823 (m), 629 (m).
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL425548(22)20180515A PL238121B1 (en) | 2018-05-15 | 2018-05-15 | Cis-(4S,5S,6R)-5-(1-bromethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one and method for obtaining it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL425548(22)20180515A PL238121B1 (en) | 2018-05-15 | 2018-05-15 | Cis-(4S,5S,6R)-5-(1-bromethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one and method for obtaining it |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL425548A1 PL425548A1 (en) | 2019-11-18 |
| PL238121B1 true PL238121B1 (en) | 2021-07-05 |
Family
ID=68536665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL425548(22)20180515A PL238121B1 (en) | 2018-05-15 | 2018-05-15 | Cis-(4S,5S,6R)-5-(1-bromethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one and method for obtaining it |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL238121B1 (en) |
-
2018
- 2018-05-15 PL PL425548(22)20180515A patent/PL238121B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL425548A1 (en) | 2019-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103601641A (en) | Glaucocalyxin derivatives and application thereof in preparation of antitumor drugs | |
| PL238121B1 (en) | Cis-(4S,5S,6R)-5-(1-bromethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one and method for obtaining it | |
| PL238122B1 (en) | Cis-(4R,5R,6S)-5-(1-bromethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one and method for obtaining it | |
| Shirouzu et al. | Synthesis of modified pyrimidine nucleosides via Vorbrüggen-type N-glycosylation catalyzed by 2-methyl-5-phenylbenzoxazolium perchlorate | |
| Bachan et al. | Synthesis and anti-tumor activity of carbohydrate analogues of the tetrahydrofuran containing acetogenins | |
| PL236838B1 (en) | trans-(4S,5R,6S)-5-(1-Bromoethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one and method of its preparation | |
| PL235029B1 (en) | (4R,5R,6S)-5-t-bromo-4-r-(2',5'-dimethylphenyl)-6-c-methyltetrahydropyran-2-one and method for obtaining it | |
| PL236837B1 (en) | trans-(4S,5R,6S)-5-(1-Bromoethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one and method of its preparation | |
| PL235028B1 (en) | (4S,5S,6R)-5-t-bromo-4-r-(2',5'-dimethylphenyl)-6-c-methyltetrahydropyran-2-one and method for obtaining it | |
| Popsavin et al. | Synthesis and biological activity of thiophene bioisosteres of natural styryl lactone goniofufurone and related compounds | |
| EP2716293B1 (en) | Anti-tumor agent | |
| Caletková et al. | Synthesis and antitumour activity of varitriol and its analogues. | |
| Zhang et al. | Design, synthesis, and preliminary evaluation of the biological activity of dithiocarbamate-3-epi-jaspine B hybrids | |
| Reddy et al. | Synthesis and biological evaluation of sapinofuranones A, B and 1, 2, 3-triazole-sapinofuranone hybrids as cytotoxic agents | |
| PL229559B1 (en) | Cis-(4S,5S,6R)-5-(1-iodoethane)-4-(2',5'-dimethylphenyl)dihydrofuran-2-one and trans-(4S,5R,6S)-5-(1-iodoethane)-4-(2',5'-dimethylphenyl)dihydrofuran-2-one and method for obtaining them simultaneously | |
| PL238102B1 (en) | (+)-rel-(1R,6R,1'R)-1-(1'-Bromoethyl)-9-oxabicyclo[4.3.0]nonan-8-one and method of obtaining (+)-rel-(1R,6R,1'R)-1-(1'-bromoethyl)-9-oxabicyclo[4.3.0]nonan-8-one | |
| Luo et al. | Facile synthesis of novel benzoylthiophene C-nucleoside analogues via coupling of sugar alkynes, aroyl chlorides, and 1, 4-dithiane-2, 5-diol | |
| PL229558B1 (en) | Cis-(4R,5R,6S)-5-(1-iodoethane)-4-(2',5'-dimethylphenyl)dihydrofuran-2-one and trans-(4S,5R,6S)-5-(1-iodoethane)-4-(2',5'-dimethylphenyl)dihydrofuran-2-one and method for obtaining them simultaneously | |
| PL238104B1 (en) | (+)-rel-(1R.6R, 1'R)-1-(1'-Chloroethyl)-9--oxabicyclo[4.3.0]nonan-8-one and method of obtaining (+)-rel-(1R .6R,1'R)-1-(1'-chloroethyl)-9-oxabicyclo[4.3.0]nonan-8-one | |
| PL239567B1 (en) | (-)-rel-(1R, 6R,1'R) -1-(1'-Iodoethyl)-9-oxabicyclo[4.3.0]nonan-8-one and method of obtaining (-)-rel-(1R,6R,1'R)-1-(1'-iodoethyl)-9-oxabicyclo[4.3.0]nonan-8-one | |
| PL221299B1 (en) | Cis- (4R, 5R, 6S) -5- (1-iodoethyl) -4- (4'-isopropylphenyl) dihydrofuran-2-one and trans- (4R, 5S, 6R) -5- (1-iodoethyl) -4- (4'-isopropylphenyl) dihydrofuran-2-one and the method of their simultaneous preparation | |
| CN109096332A (en) | A kind of chlorinated triphenyl base -4-(trifluoromethyl Benzamido) fourth base Phosphonium synthetic method and its application in anti-tumor drug | |
| PL231187B1 (en) | Trans-(4R,5S,6R)-4-(benzo[d][1',3']-dioxol-5'-yl)-5-(1-iodo-ethyl)-dihydrofuran and method for obtaining it | |
| PL231188B1 (en) | Trans-(4S,5R,6S)-4-(benzo[d][1',3']-dioxol-5'-yl)-5-(1-iodoethyl)-dihydrofuran-2-one and method for obtaining it | |
| PL238103B1 (en) | (-)-rel-(1R,6R,1'R)-1-(1'-Chloroethyl)-9-oxabicyclo[4.3.0.]nonan-8-one and method of obtaining (-)-rel-(1R ,6R,1'R)-1-(1'-chloroethyl)-9-oxabicyclo[4.3.0]nonan-8-one |